Friday, 28 Feb 2020

You are here

Two-Fold Increase of Demyelinating Diseases with TNF Inhibition

Despite the potential contributory role of TNF in the pathogenesis of multiple sclerosis, several trials have shown that TNF inhibitor (TNFi) use may lead to worsening of MS, optic neuritis and other demyelinating disorders. This particular safety warning has been in the product label for nearly 15 years, yet little is known about why this happens, how often or what the scope of potentially inducible neurologic disease may be.

Researchers in Denmark investigated this potential association between demyelinating disease and inflammatory bowel disease (IBD) and those receiving TNFi for their IBD.

Using a national population-based cohort, they compared rates of central demyelinating diseases among patients with IBD exposed and unexposed to anti-TNF to data drawn from the Danish Civil Registration System, between January 1, 1999, to December 31, 2012.

The neurologic outcomes of interest were defined as a diagnosis of a central demyelinating disease, which includes multiple sclerosis, optic neuritis, transverse myelitis, and other central demyelinating diseases. Patients with a history of demyelinating diseases and those taking TNFi prior to 1999 or prior to IBD diagnosis were excluded.

Among 54843 IBD patients, 4504 received TNFi and were compared to 16,429 unexposed patients. IBD patients were roughly 40 yrs. of age with a mean disease duration 4.0 years.
When comparing TNFi exposed to unexposed (controls) patients, there were 11 demyelinating events in the exposed and 17 demyelinating events in the unexposed controls. Thus, higher rates were seen in the exposed vs. unexposed (7.5 events per 10000 person-years [95% CI, 4.1-13.5] vs. 3.3 events per 10000 person-years [95% CI, 2.1-5.4]).

Exposed patients with demyelinating disease had 2 cases of multiple sclerosis; 5 optic neuritis; and 4 other central demyelinating diseases. Unexposed patients had 5 multiple sclerosis; 6 optic neuritis; 1 transverse myelitis; 5 other central demyelinating diseases.

Overall, there was a two-fold increased risk of central demyelinating disease when using a TNFi in patients with IBD (HR 2.19 [95% CI, 1.02- 4.71]).

These findings support the potential association and the practice of avoiding TNFi in patients with MS, optic neuritis or other demyelinating disorders. There is little evidence that TNFi worsens or affects other degenerative or inflammatory neurologic disorders.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Overmedication of America

Recent research from the Lown Institute reports that 750 older Americans are hospitalized daily because of serious side effects from and the core problem is that of polypharmacy, especially in the elderly. 

Best of 2019 - Biologic Safety Guidelines from the British Society for Rheumatology

In the United Kingdom, NICE has looked to the British Society of Rheumatology (BSR) to develop evidence based guidance on the safe use of biologic DMARDs in patients with inflammatory arthritis. This guidance document on biologic safety covers baseline screening, monitoring, effect of co-morbidities, and when or under what circumstances biologic therapy should be interrupted.

Best of 2019 - Methotrexate and the Risk of Lung Disease

Rheumatology has a comprehensive overview of methotrexate (MTX) and the risk of lung injury, MTX-related pneumonitis and interstitial lung disease (RA-ILD) with rheumatoid arthritis (RA). Past reports suggest the frequence of MTX-pneumonitis to be between 0.3 and 11.6%; recent studies suggest it may be much lower.

No Cancer Risk with Systemic Necrotizing Vasculitis

The French Vasculitis Study Group has published that patients with systemic necrotizing vasculitis do not have an increased risk of malignancy; in fact they have a risk that is similar to the general population.

Previous reports have suggested either no risk or a declining risk in the era of better therapies for vasculitis. 

FDA Warns 15 CBD Manufacturers

Today, the U.S. Food and Drug Administration issued warning letters to 15 companies for illegally selling products containing cannabidiol (CBD) in ways that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act).  This warning affirms that the FDA has not determined the many preparations of cannabidiol to be safe or effective.